April 30, 2025 11:05 AM EDT

The Endpoints Slack interview: Arc Institute's Patrick Hsu on investing, AI and new ways of research

Andrew Dunn

Senior Biopharma Correspondent

Science is full of wunderkinds. But 31-year-old Patrick Hsu has already been on the frontiers of academic science, the biotech industry and now the world …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The Endpoints Slack interview: Arc Institute's Patrick Hsu on investing, AI and new ways of research

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Exits continue at FDA, as more staff in drug office follow fired colleagues out the door

Updated: Novartis to buy Regulus Therapeutics for up to $1.7B

FDA won't reorganize medical product centers, Makary says in interview: 'I rejected that proposal'

FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts

FDA approves J&J's rare disease drug that's expected to compete with argenx and UCB

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

The End­points Slack in­ter­view: Arc In­sti­tute's Patrick Hsu on in­vest­ing, AI and new ways of re­search

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Ex­its con­tin­ue at FDA, as more staff in drug of­fice fol­low fired col­leagues out the door

Up­dat­ed: No­var­tis to buy Reg­u­lus Ther­a­peu­tics for up to $1.7B

FDA won't re­or­ga­nize med­ical prod­uct cen­ters, Makary says in in­ter­view: 'I re­ject­ed that pro­pos­al'

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

FDA ap­proves J&J's rare dis­ease drug that's ex­pect­ed to com­pete with ar­genx and UCB

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

The Endpoints Slack interview: Arc Institute's Patrick Hsu on investing, AI and new ways of research

Exits continue at FDA, as more staff in drug office follow fired colleagues out the door

Updated: Novartis to buy Regulus Therapeutics for up to $1.7B

FDA won't reorganize medical product centers, Makary says in interview: 'I rejected that proposal'

FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts

FDA approves J&J's rare disease drug that's expected to compete with argenx and UCB

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?